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ABSTRACT
Introduction: Treatment-related quality of life
(QOL) is an important aspect of diabetes man-
agement. Here, we investigated the influence of
sitagliptin, a dipeptidyl peptidase-4 inhibitor,
on treatment-related QOL in patients with type
2 diabetes mellitus treated with insulin.
Methods: This was a prespecified sub-analysis
of the Sitagliptin Preventive Study of
Intima-Media Thickness Evaluation (SPIKE).
The study population consisted of 71 subjects in
the sitagliptin group, and 62 subjects in the
conventional group who were treated with
insulin. Patients of the sitagliptin group were
started on sitagliptin in addition to ongoing
insulin therapy. In the conventional group,
either increasing the dose of current insulin
therapy or the addition of oral hypoglycemic
agents other than dipeptidyl peptidase-4 inhi-
bitors was allowed to achieve glycemic control.
Treatment-related QOL was evaluated before
and 104 weeks after the initiation of the study
using the Diabetes Therapy-Related QOL Ques-
tionnaire 7 (DTR-QOL7).
Results: Forty-five out of 71 subjects in the
sitagliptin group and 41 out of 62 subjects in
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the conventional group filled out the QOL
questionnaire at week 104. The DTR-QOL7
score at week 104 was significantly increased
from baseline in the sitagliptin group, while
that in the conventional group was not chan-
ged. However, the changes in score did not
differ between the two groups. Change in
HbA1c was negatively associated with change in
score.
Conclusions: Our data suggest that sitagliptin
added to insulin treatment was comparable to
other treatments in terms of its impact on
treatment-related QOL.
Clinical Trial Registration: ClinicalTrials.gov
identifier: UMIN000007396.
Funding: Mitsubishi Tanabe Pharma Co., Ono
Pharmaceutical Co., and Novo Nordisk.
Keywords: Sitagliptin; Treatment-related
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INTRODUCTION
One of the main goals in the management of
type 2 diabetes (T2DM) is to maintain quality of
life (QOL). Effective treatment needs to achieve
these goals by taking into account many factors,
including age, disease duration, glycemic con-
trol status, physical status, and diabetic com-
plications. In terms of choosing oral
hypoglycemic agents, consideration of treat-
ment-related QOL is important because it has
been recognized as an important factor associ-
ated with patient motivation and adherence [1].
This is crucial since poor adherence to T2DM
treatment has been shown to be associated with
poor glycemic control and increased risk of
mortality [2]. The American Diabetes Associa-
tion therefore emphasized the importance of
considering patient preference in addition to
efficacy, hypoglycemic risk, impact on weight,
potential side effects, and cost [3].
Hypoglycemia and weight gain are common
side effects of treatment for T2DM [4] and the
major barrier to achieving optimal glycemic
control, especially with insulin therapy. In this
regard, treatment with insulin plus metformin
[5] and a-glucosidase inhibitors [6], but not
pioglitazone [7] or sulfonylurea [8], were
advantageous in avoiding both weight gain and
hypoglycemia. However, there are treat-
ment-limiting side effects with a-glucosidase
inhibitors or metformin such as gastrointestinal
symptoms [6, 9]. These treatment-limiting side
effects may be associated with reduction in
treatment-related QOL in patients. Dipeptidyl
peptidase-4 (DPP-4) inhibitors reduced blood
glucose levels through increasing insulin secre-
tion and suppressing glucagon release and are
generally safe and well tolerated without
increasing body weight [10, 11]. As a result of
these characteristics, DPP-4 inhibitors are
widely prescribed in Japan. In addition, sita-
gliptin was shown to improve QOL in patients
treated with oral hypoglycemic agents in a sin-
gle-arm study [12].
In addition, DPP-4 inhibitors are sometimes
administered to patients receiving insulin;
however, treatment-related QOL in this popu-
lation has not yet been elucidated. Recently, we
conducted the Sitagliptin Preventive Study of
Intima-Media Thickness Evaluation (SPIKE)
study to investigate the effect of sitagliptin, a
DPP-4 inhibitor, on carotid atherosclerosis and
reported that sitagliptin slowed the progression
of carotid intima-media thickness in
insulin-treated T2DM patients [13]. However,
there are few studies that investigate the effect
of DPP-4 inhibitors on QOL in patients treated
with insulin while recent studies demonstrated
that the addition of DPP-4 inhibitors to insulin
therapy improved blood glucose levels without
increased risk for hypoglycemia and increasing
body weight [13, 14]. The present study was
originally planned as a sub-analysis of the SPIKE
study to investigate the effect of sitagliptin on
treatment-related QOL in patients treated with
insulin.
METHODS
Study Population
We performed a sub-analysis of the SPIKE study,
whose methods were described in detail previ-
ously [15]. Briefly, a total of 282 insulin-treated
Japanese T2DM patients free of a past history of
apparent cardiovascular disease were randomly
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allocated to either the sitagliptin group
(n = 142) or the conventional treatment group
(using oral hypoglycemic agents other than the
DPP-4 inhibitor) (n = 140). Patients were inclu-
ded regardless of the number of insulin injec-
tions or type of insulin. Randomization is
performed using a dynamic allocation method
based on the number of insulin injections,
with/without pioglitazone, age, and gender. In
the conventional treatment group, either
increasing the dose of current therapy (e.g.,
insulin) or the addition of sulfonylurea, glinide,
and a-glucosidase inhibitors is allowed with the
goal of achieving the target value specified in
the Treatment Guide for Diabetes (usually
HbA1c level less than 6.9% and/or fasting blood
glucose less than 130 mg/dl and/or 2 h post-
prandial blood glucose less than 180 mg/dl) [16]
at each medical provider’s discretion. The
addition of other DPP-4 inhibitors and gluca-
gon-like peptide-1 analogues is banned in the
control group. The dose adjustment and addi-
tion of metformin and pioglitazone are banned
in both groups during the study. In case of
hypoglycemia, the dose of insulin and/or oral
hypoglycemic agents is titrated. All patients
who agreed to participate were entered into the
study and signed written informed consent. The
SPIKE study was registered with the University
Hospital Medical Information Network Clinical
Trials Registry (UMIN000007396) and meets the
requirements of the International Committee of
Medical Journal Editors.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation (insti-
tutional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
Diabetes Therapy-Related QOL
Questionnaire (DTR-QOL) 7
The DTR-QOL is a reliable and valid question-
naire developed by Ishii; it is a 29-item,
self-administered assessment with four primary
factors [17]. As a result of practical constraints
we created a short version, the DTR-QOL7. This
involved selecting six questions from the origi-
nal 29 items by considering relationships
among items based on the results of the original
study. Of the 23 excluded items, we chose to
include one (Q2) that asked about weight gain
with treatment because this factor is likely to
have a major impact on QOL based on clinical
experience. Unfortunately, the way of selecting
seven questions from the original 29 items was
not based on technical or statistical rationales.
However, we confirmed that all six items other
than Q2 seemed to be included in the same
domain, suggesting that the structure of the
DTR-QOL7 was relatively consistent in the
original study. The total scores of DTR-QOL7
except Q2 had high internal consistency based
on Cronbach’s alpha coefficients (data not
shown) and were highly associated with the
total scores of the original 29 items. The items
included are shown in Table 1. The response to
each question consisted of a 7-point Likert-type
scale that ranged from 1 (strongly agree) to 7
(strongly disagree). The scales of Q5, Q6, and Q7
were reversed so that 7 represented the highest
QOL score. The total score, after simple addition
of each item score, was converted to a range
from 0 to 100 (best-case response = 100;
worst-case response = 0). The score of Q2 was
evaluated separately. We treated missing values
according to the original DTR-QOL [17]. We
measured the DTR-QOL7 at baseline and at
104 weeks.
Statistical Analysis
Results are presented as mean ± SD, median
(quantile 1 and quantile 3), or number (pro-
portion) of patients. Factor analysis was per-
formed on the seven items to investigate
whether the structure of the DTR-QOL7 was
consistent. Variables with factor loading of at
least 0.30 were considered for interpretation.
The internal consistency of the total score and
each domain of the DTR-QOL7 was assessed
using Cronbach’s alpha coefficient. An alpha of
at least 0.70 is considered acceptable for the
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purpose of group comparisons [18]. Baseline
and follow-up group comparisons were assessed
with the Student’s t test or Wilcoxon’s rank sum
test for continuous variables and Fisher’s exact
test for categorical variables. Changes from
baseline to treatment visits were assessed with
one-sample t test or Wilcoxon’s signed rank test
for continuous variables and McNemar’s test for
Table 1 DTR-QOL7 questionnaire
Q1. I am constantly concerned about time to manage my current diabetes treatment
Q2. I am bothered by weight gain with my current diabetes treatment
Q3. I am sometimes bothered by low blood glucose
Q4. I am worried about high blood glucose
Q5. Overall, I am satisﬁed with my current blood sugar control
Q6. With my current diabetes treatment, I am conﬁdent that I can maintain good blood glucose control
Q7. With regards to diabetes treatment, I am satisﬁed with current treatment methods
Table 2 Clinical characteristics of patients in the sitagliptin and conventional treatment groups
Parameters Sitagliptin treatment
group (n5 71)
Conventional treatment
group (n5 62)
P value
Age (years) 62.6 ± 11.7 63.6 ± 9.5 0.59
Gender (male) (%) 40 (56.3) 31 (50) 0.49
Duration of diabetes (years) 16.8 ± 8.3 17.2 ± 8.3 0.77
eGFR (mL/min/1.73 m2) 77.8 ± 20.8 79.5 ± 22.3 0.65
Body mass index (kg/m2) 25.7 ± 4.4 25.3 ± 4.0 0.57
HbA1c (%) 8.3 ± 1.2 8.0 ± 1.1 0.15
Total daily insulin dosage (IU/day) 32.3 ± 22.8 29.4 ± 22.3 0.46
Time of insulin injections (times/day) 3.0 ± 1.1 3.1 ± 1.0 0.77
Type of insulin
Prandial insulin (yes) 41 (57.7) 39 (62.9) 0.60
Premixed insulin (yes) 35 (49.3) 18 (29) 0.02
Basal insulin (yes) 31 (43.7) 33 (53.2) 0.30
Use of oral glucose-lowering agents
Metformin (yes) 31 (43.7) 25 (35.5) 0.38
Sulfonylurea (yes) 11 (15.5) 8 (12.9) 0.81
Glinides (yes) 0 (0) 0 (0) –
Thiazolidinediones (yes) 9 (12.7) 4 (6.5) 0.26
a-Glucosidase inhibitor (yes) 31 (43) 24 (38.7) 0.60
Data are number (%) of patients or mean ± SD
HbA1c glycated hemoglobin A1c, eGFR estimated glomerular ﬁltration rate
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binary variables within the group. Differences
in delta change in score of QOL from baseline to
104 weeks between groups were analyzed with
analysis of covariance adjusted for score at
baseline. All statistical tests were two-sided with
a 5% significance level. All analyses were per-
formed using the SAS software version 9.4 (SAS
Institute, Cary, NC).
RESULTS
Baseline Characteristics
Among patients in the original study, 71 in the
sitagliptin group and 62 in the conventional
group completed the DTR-QOL questionnaire at
baseline. Baseline clinical characteristics were
comparable between the two groups (Table 2). At
week 104, 45 in the sitagliptin group and 41 in
the conventional group completed the DTR-QOL
questionnaire. Consequently, 47 subjects did not
complete the DTR-QOL questionnaire. In the
comparison of clinical characteristics at baseline
between subjects who completed the DTR-QOL
questionnaire and those who did not, there were
statistical significant differences in total daily
insulin dosage, the use of prandial insulin, and
the use of metformin and a-glucosidase inhibi-
tors between subjects who completed the
DTR-QOL questionnaire and those who did not
(Table 3). On the other hand, there were no sig-
nificant differences in clinical parameters at
baseline between patients who completed the
Table 3 Baseline clinical characteristics of patients who completed questionnaire and who did not complete questionnaire
Parameters Completion of questionnaire
at week 104 (n5 86)
No completion of questionnaire
at week 104 (n5 47)
P value
Age (years) 63.9 ± 10.0 61.5 ± 11.8 0.22
Gender (male) (%) 44 (51.2) 27 (57.4) 0.59
Body mass index (kg/m2) 25.7 ± 4.1 25.1 ± 4.5 0.37
Duration of diabetes (years) 17.7 ± 8.6 15.6 ± 7.7 0.16
HbA1c (%) 8.2 ± 1.2 8.1 ± 1.2 0.50
eGFR (mL/min/1.73 m2) 77.4 ± 20.6 80.7 ± 22.9 0.39
Total daily insulin dosage (IU/day) 33.0 ± 24.1 27.3 ± 18.8 0.046
Time of insulin injections (times/day) 3.2 ± 1.0 2.8 ± 1.1 0.16
Type of insulin
Prandial insulin (yes) 58 (67.4) 22 (46.8) 0.026
Premixed insulin (yes) 35 (49.3) 21 (44.7) 0.46
Basal insulin (yes) 42 (48.8) 22 (46.8) 0.86
Use of oral glucose-lowering agents
Metformin (yes) 25 (25.9) 28 (59.6) \0.001
Sulfonylurea (yes) 14 (16.3) 5 (10.6) 0.45
Glinides (yes) 0 (0) 0 (0) –
Thiazolidinediones (yes) 10 (11.6) 3 (6.4) 0.38
a-Glucosidase inhibitors (yes) 21 (24.4) 34 (72.3) \0.001
Data are number (%) of patients or mean ± SD
HbA1c glycated hemoglobin A1c, eGFR estimated glomerular ﬁltration rate
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DTR-QOL questionnaire in the sitagliptin group
and those who did in the conventional group
(Table 4). The addition of sitagliptin to insulin
therapy significantly reduced HbA1c level from
baseline to week 104 (Table 4). The change in
HbA1c level from baseline to week 104 was
numerically greater in subjects who completed
the DTR-QOL questionnaire of the sitagliptin
group than in subjects who completed it in the
conventional group; however, there was no sig-
nificant difference between the two groups
(-0.6 ± 1.4 vs. -0.3 ± 1.0%, P = 0.23). On the
other hand, there were no differences between
the two groups in change in body mass index
(-0.3 ± 2.1 vs. 0.3 ± 2.5 kg) or in the average
number of hypoglycemic episodes [0.0 (0.0, 0.4)
vs. 0.0 (0.0, 0.3) times/month/person] over
104 weeks (data not shown).
Factor Analysis and Internal Consistency
Factor analysis with promax rotation was per-
formed to investigate the structure of the
DTR-QOL7 (Table 5). As expected, all six items
other than Q2 seemed to be included in the
Table 4 Comparison of clinical parameters at baseline and week 104
Parameters Sitagliptin treatment
group (n5 45)
Conventional treatment
group (n5 41)
P value (intergroup)
Baseline Week 104 Baseline Week 104 Baseline Week 104
Age (years) 62.6 ± 11.9 – 65.4 ± 7.2 – 0.19 –
Gender (male) (%) 25 (55.6) – 19 (46.3) – 0.52 –
Body mass index (kg/m2) 26.1 ± 4.4 25.8 ± 4.5 25.3 ± 3.7 25.6 ± 4.7 0.37 0.82
Duration of diabetes (years) 17.1 ± 8.7 – 18.4 ± 8.4 – 0.50
HbA1c (%) 8.4 ± 1.2 7.7 ± 1.7** 8.0 ± 1.1 7.7 ± 1.3 0.21 0.51
eGFR (mL/min/1.73 m2) 78.3 ± 21.3 73.6 ± 25.8** 76.4 ± 20.0 73.5 ± 21.2 0.67 0.98
Total daily insulin dosage (IU/day) 3.2 ± 1.1 2.9 ± 1.3 3.2 ± 0.9 3.2 ± 1.0 0.77 0.35
Time of insulin injections (times/day) 34.5 ± 24.6 30.2 ± 22.7* 31.4 ± 23.8 29.0 ± 19.7 0.56 0.79
Type of insulin
Prandial insulin (yes) 30 (66.7) 28 (65.1) 28 (68.7) 28 (68.7) 1.00 0.82
Premixed insulin (yes) 18 (40.0) 15 (34.9) 14 (34.1) 11 (26.8) 0.66 0.48
Basal insulin (yes) 24 (53.3) 25 (58.1) 18 (43.9) 23 (56.1) 0.40 1.00
Use of oral glucose-lowering agents
Metformin (yes) 15 (33.3) 15 (33.3) 10 (24.4) 9 (22.0) 0.48 0.34
Sulfonylurea (yes) 8 (17.8) 8 (17.8) 6 (14.6) 7 (17.1) 0.79 1.00
Glinides (yes) 0 (0) 1 (2.2) 0 (0) 1 (2.4) – 1.00
Thiazolidinediones (yes) 8 (17.8) 8 (17.8) 2 (4.9) 2 (4.9) 0.09 0.09
a-Glucosidase inhibitor (yes) 12 (26.7) 12 (24.4) 9 (22) 9 (22) 0.63 0.80
Data are number (%) of patients or mean ± SD values
Changes from baseline to week 104 were assessed with by one-sample t test or Wilcoxon’s signed rank test for continuous
variables and McNemar’s test for binary variables within the group: * P\0.05, ** P\0.01
HbA1c glycated hemoglobin A1c, eGFR estimated glomerular ﬁltration rate
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same domain, suggesting that the structure of
the DTR-QOL7 was relatively consistent.
According to internal consistency analysis of
the DTR-QOL7, all six items except for Q2
showed moderate internal consistency, with a
Cronbach’s alpha coefficient of 0.71. The result
of the factor analysis at 104 weeks was almost
similar to that at baseline (data not shown).
Temporal Change in DTR-QOL7 Scores
Both at baseline and at 104 weeks, there were no
differences between the two groups in the total
DTR-QOL7 score (excluding Q2) or in the score
of each individual question (Q1–Q7), as shown
in Table 6. The total DTR-QOL7 score and the
scores of Q5 and Q6 were significantly increased
at 104 weeks compared to baseline in the sita-
gliptin group. In the conventional group there
were no significant score changes over time.
There were no significant differences between
the two groups in changes from baseline to
week 104 of the total DTR-QOL7 score or the
score of any individual question (Q1–Q7).
We investigated the relationship between
changes in total DTR-QOL7 score and changes
in various parameters. The change in HbA1c at
week 104 was negatively associated with change
in total DTR-QOL7 score (Spearman’s correla-
tion coefficient, r = -0.35, P\0.001); age at
baseline, gender, body mass index at baseline,
duration of T2DM, and type of treatment
showed no association (data not shown). Also,
the occurrence of hypoglycemia showed nega-
tive, non-significant association with change in
total DTR-QOL7 score (r = -0.21, P = 0.05).
DISCUSSION
In this study, sitagliptin treatment increased the
score of DTR-QOL7 from baseline while con-
ventional treatment resulted in no change. On
the other hand, there were no significant differ-
ences in the use of oral glucose-lowering agents
other thanDPP-4 inhibitors between two groups.
Thus, increase in the score of DTR-QOL7 may be
associated with sitagliptin used as an add-on
therapy to insulin itself. However, the change in
DTR-QOL7 score did not differ between the two
groups. Taken together, these resultsmay suggest
that sitagliptin added to insulin treatment was
comparable to other treatments in terms of its
impact on treatment-related QOL.
A previous report demonstrated that gly-
cemic control was associated with higher treat-
ment-related QOL [17]. In this study, change in
HbA1c level was negatively associated with
change in the total DTR-QOL7 score. Thus, it is
reasonable to hypothesize that sitagliptin
treatment improved QOL by increasing patient
satisfaction with aspects of treatment related to
glycemic control (Q5 and Q6). On the other
hand, adverse effects and patient acceptance of
treatment may worsen treatment-related QOL.
In particular, more frequent hypoglycemic epi-
sodes have a harmful effect on QOL [19, 20]. In
addition, weight gain caused by diabetes treat-
ment may be an undesired feature and nega-
tively affects QOL. With respect to these issues,
sitagliptin treatment did not worsen QOL as
shown by constant scores on Q2 and Q3. These
findings are reasonable considering that sita-
gliptin treatment did not increase body weight
or risk of hypoglycemia compared to conven-
tional treatment.
The present study has certain limitations.
First, the studywas a sub-analysis that included a
relatively small sample from the original study
because the questionnaire was completed on a
voluntary basis. This may have caused selection
Table 5 Seven items on the DTR-QOL7 and factor
analysis with promax rotation (n = 131)
Question number Factor 1
Q1 0.36
Q2 -0.02
Q3 0.43
Q4 0.46
Q5 0.68
Q6 0.76
Q7 0.58
Individual question items with a factor loading of[|0.3|
are shown in bold
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bias. In addition, there were statistically signifi-
cant differences in total daily insulin dosage, the
use of prandial insulin, and the use ofmetformin
and a-glucosidase inhibitors between subjects
who completed the DTR-QOL questionnaire and
those who did not. Although we could not rule
out the possibility that obtained data did not
reflect the characteristics of the original popula-
tion, there were no significant differences in
clinical parameters at baseline between subjects
who completed the DTR-QOL questionnaire in
the two groups. Second, we evaluated treat-
ment-related QOL using only the DTR-QOL7. Its
small number of questions is a weakness in terms
of evaluating the many ways that diabetes treat-
ment can influence QOL. However, we con-
firmed that the structure of the DTR-QOL7 was
consistent and that it had moderate internal
consistency. Further studies are required to con-
firm our findings.
CONCLUSIONS
Our data suggest that sitagliptin treatment did
not worsen treatment-related QOL compared to
conventional treatment, at least when used as
an add-on therapy to insulin.
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